BOSTON--(BUSINESS WIRE)--Oncomatrix, a biopharmaceutical company that develops biological treatments against invasive tumors, has licensed from National Jewish Health an intellectual property portfolio claiming the use of the human protein Cystatin-C to treat cancer. “We are committed to focusing our resources and enthusiasm to exploit the antitumoral activity of Cystatin-C in the development of a new generation of drugs to treat invasive tumors,” said Laureano Simon, PhD, CEO of Oncomatrix, SL.